Literature DB >> 18835626

Signet-ring stromal tumor of the testis: a case report and literature review.

Chen Yun Kuo1, Mei Chin Wen, John Wang, Yee Jee Jan.   

Abstract

Primary signet-ring stromal tumor of the testis is extremely rare. To our knowledge, only one case has been reported in the literature. Herein, we present a case of testicular signet-ring stromal tumor with positive immunostain for CD99, which has not been reported previously. We also review the literature and discuss the clinicopathological significance of this type of tumor. The most important differential diagnosis of signet-ring stromal tumor is metastatic signet-ring cell carcinoma because of its different management and prognosis. Fortunately, signet-ring stromal tumors have a well-defined growth pattern, bland histological features, no mucin production, and immunoreaction to vimentin rather than cytokeratin, all of which help pathologists to rule out metastatic adenocarcinoma. Although ovarian signet-ring stromal tumors are categorized in the fibroma/thecoma group of sex cord stromal tumors, the cell origin of signet-ring stromal tumors is still debatable. The histological criteria for predicting clinical behavior of signet-ring stromal tumors are not clear. Fortunately, however, all reported signet-ring stromal tumors are benign tumors with excellent prognosis, and they do not recur or metastasize. We consider signet-ring stromal tumor to be a special type of sex cord stromal tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835626     DOI: 10.1016/j.humpath.2008.07.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

Review 1.  [New 2022 WHO classification of testicular tumours].

Authors:  Alexander Fichtner; Philipp Ströbel; Felix Bremmer
Journal:  Pathologie (Heidelb)       Date:  2022-09-21

2.  Signet ring cell-type adenocarcinoma arising in a mature teratoma of the testis.

Authors:  Hong Koo Ha; Wan Lee; Sang Don Lee; Jeong Zoo Lee; Moon Kee Chung
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.